Objective. Cyclooxygenase-2 inhibitors (coxibs) are associated with less upper gastrointestinal bleeding (UGIB) than traditional nonsteroidal antiinflammatory drugs (tNSAIDs). However, they also increase the risk of UGIB in high-risk patients. We aimed to identify the risk factors of UGIB in coxibs users.
Subjects. Patients taking coxibs as the study group and patients not taking any coxibs as controls.
Methods. After age, gender, and comorbidity matching by propensity score, 12,145 coxibs users and 12,145 matched controls were extracted for analysis. The primary end point was the occurrence of UGIB. Cox multivariate proportional hazard regression models were used to determine the risk factors for UGIB among all the enrollees and coxibs users.
Results. During a mean follow-up of three years, coxibs users had significantly higher incidence of UGIB than matched controls (P < 0.001, log-rank test). Cox regression analysis showed that coxibs increased risk of UGIB in all participants (hazard ratio 5 1.37, 95% confidence interval 5 1.19-1.55, P < 0.001). Independent risk factors for UGIB among coxibs users were age, male gender, diabetes, chronic renal disease, cirrhosis, history of peptic ulcer disease, PU bleeding (PUB), Helicobacter pylori (H. pylori) infection, and concomitant use of tNSAIDs, acetylsalicylic acid, or thienopyridines.
Conclusions. Among coxibs users, H. pylori infection and history of PUB were especially important risk factors for UGIB. Further studies are needed to determine whether proton pump inhibitors might play a protective role in these at-risk patients.
Introduction
In addition to acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs) including cyclooxygenase (COX)-2 selective inhibitors (coxibs) are the most commonly used drugs for pain relief and anti-inflammation [1, 2] . Traditional NSAIDs (tNSAIDs) inhibit both the constitutive COX-1 and inducible COX-2 isoforms of COX. The inhibition of COX-2 is mostly responsible for the therapeutic effects of NSAIDs, while the adverse gastrointestinal (GI) effects of NSAIDs are attributable to the inhibition of both COX-1 and COX-2, which decreases prostaglandin synthesis, impairs the maintenance of GI mucosal integrity, and results in erosion, ulceration, and bleeding [3, 4] . Coxibs selectively inhibit COX-2 and thus inhibit inflammation while preserving most of the homeostatic functions of COX-derived prostaglandins.
Several studies have demonstrated that the use of coxibs is associated with fewer upper GI events than tNSAIDs [3] [4] [5] . A meta-analysis study showed that there was no greater risk of PUD from low-dose coxibs than from a placebo. However, high-dose coxibs seemed to increase the risk of PUD compared with placebo, although these trends did not have statistical significance [6] . Some studies have found that the use of coxibs may not be safe in patients with a history of NSAID-associated ulcer complications [7] [8] [9] .
Few studies have evaluated whether coxibs are less safe than not taking coxibs in regard to PUB or upper GI bleeding (UGIB). The aim of this study is to evaluate whether coxibs usage increases the risk of UGIB and to identify the risk factors of UGIB in coxibs users in a nationwide population-based cohort study.
Methods

Database
The National Health Insurance (NHI) program in Taiwan was established in 1995 to provide comprehensive medical care and currently covers more than 99% of the population of 23 million. The NHI research database (NHIRD) was established in cooperation with the Bureau of National Health Insurance (BNHI) and the National Health Research Institute (NHRI). This database is one of the largest administrative health care databases in the world and is available to scientists for research purposes [10, 11] .
The present study analyzes data from the Longitudinal Health Insurance Database (LHID2000) from the NHRI, which includes a cohort data set of one million randomly sampled individuals. The database consists of comprehensive health care data including enrollment files, claims data, and the registry for drug prescriptions [10, 11] . In the cohort data set, each patient's original identification number is encrypted for privacy. Disease diagnosis was based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). This study was approved by the Institutional Review Committee of Taipei Veterans General Hospital (Institutional Review Board: 2013-04-038BC).
Study Subjects
All enrollees were traced retrospectively to the year 2000 and followed up until 2010. There were no statistically significant differences in gender, age, and health care costs between patients in the LHID2000 and those in the original NHIRD. Patients were enrolled as coxibs users if they were older than 20 years and took celecoxib, etoricoxib, or rofecoxib (the only three commercially available coxibs in Taiwan) for more than 14 days within any one-month period. Patients were excluded from the study group during screening and follow-up if they had other associated risks for UGIB, including alcohol-related diseases (ICD-9-CM codes 291.xx, 303.xx, 305.xx), malignancy of the GI tract (150.xx, 151.xx, 152.xx, 153.xx, 154.xx), inflammatory bowel disease (556.x, 555.x), coagulopathy (286.xx), vascular insufficiency of the intestine (557.xx), or gastroenteritis or colitis due to radiation (558.1) before and after January 1, 2000. These patients were excluded to avoid enrolling UGIB cases with possible causes other than coxibs use and to reduce miscoding of ICD-9-CM [11] .
We divided the patients into low-dose coxibs users (etoricoxib 30 or 60 mg, celecoxib 100 or 200 mg, rofecoxib 25 mg per day) and high-dose users (etoricoxib 90 or120 mg, celecoxib 400 mg, rofecoxib 50 mg per day). Using the same exclusion criteria as the study group, a group of controls who had not taken any coxibs was selected from the same cohort data set at a 1:1 ratio (study: control). The controls were matched by propensity score for age, sex, underlying comorbidities (hypertension, diabetes, coronary artery disease, diabetes mellitus, chronic kidney disease [CKD], chronic obstructive pulmonary disease [COPD], liver cirrhosis, ischemic stroke, uncomplicated PUD, and PUB). The controls were also matched with the study group in terms of the time of enrollment.
Patients were not excluded if they took other tNSAIDs for less than eight days within any one-month period. However, we excluded patients who took tNSAIDs for more than seven days to avoid patients whose UGIB could be attributed to tNSAIDs use instead of coxibs use.
Outcomes, Comorbidities, Medications, and Helicobacter Pylori Infection
The primary end point was the occurrence of nonvariceal UGIB as a major diagnosis during hospitalization .4x, and 534.6x). A comorbidity was defined as a corresponding ICD-9-CM code in primary hospitalization claims data once or as three times in outpatient claims before enrollment [12, 13] .
Medications were identified and classified according to the National Drug Code and the Anatomic Therapeutic Chemical codes, an internationally accepted classification systems of drugs coordinated by the World Health Organization Collaborating Center for Drug Statistics Methodology [12, 13] . The medications identified included acetylsalicylic acid (ASA; low-dose), NSAIDs (oral or parenteral), coxibs, steroids (oral or parenteral), thienopyridines (clopidogrel and ticlopidine), warfarin, dipyridamole, and selective serotonin reuptake inhibitors (SSRIs). The use of these medications was defined as a prescription of these medications for more than five days within 14 days before the index date or censoring.
The status of H. pylori was generally determined using rapid urease tests or a histological assessment using modified Giemsa staining [14] . The definition of H. pylori infection was based on the prescription of medication for H. pylori eradication with a triple or quadruple therapy consisting of proton pump inhibitors (PPIs), clarithromycin, tetracycline, amoxicillin, or metronidazole, with or without bismuth [15] .
Statistical Analysis
Microsoft SQL Server 2005 was used for data management and computing. All statistical analyses were performed using SPSS software (version 18.0, SPSS Inc., Chicago, IL, USA). Demographic data were expressed as frequencies (percentages) or as the mean 6 standard deviation. Parametric continuous data between the study and control groups were compared using the Student's t test, while categorical data were compared using the chi-square test and Yates' correction or Fisher's exact test where appropriate.
The cumulative incidence of UGIB was assessed using Kaplan-Meier analysis, with significance based on the log-rank test. Variables with statistical significance (P < 0.05) or close to it (P < 0.1) according to univariate analysis were subjected to multivariate analysis via the Cox proportional hazard regression model. This was done to identify the risk factors for UGIB among all the enrollees and the coxibs users.
Results
Baseline Characteristics
The demographic data of the study and matched control groups are shown in Table 1 . There were no significant differences between these two groups in age, gender, and rate of underlying comorbidities, including hypertension, coronary artery disease, diabetes, COPD, CKD, cirrhosis, ischemic stroke, history of uncomplicated PUD, and PUB. However, the coxibs group had significantly higher rates of concomitant use of tNSAIDs, ASA, steroids, warfarin, thienopyridines, and dipyridamole compared with the controls (Table 1) .
Outcomes
During a mean follow-up of three years, 368 (3.03%) patients in the coxibs group and 330 (2.72%) in the control group developed UGIB. The cumulative hazard of UGIB according to Kaplan-Meier analysis showed that the coxibs group had a significantly higher hazard for UGIB than the matched control group (P < 0.001) (Figure 1 ). According to univariate Cox regression analysis, risk factors for developing UGIB among all of the enrollees were age, male gender, hypertension, diabetes mellitus, CKD, cirrhosis, ischemic stroke, history of uncomplicated PUD, PUB, and the use of tNSAIDs, coxibs, ASA, dipyridamole, steroids, or thienopyridines.
Multivariate Cox regression analysis after adjusting for these risk factors showed that use of coxibs increased the risk of UGIB (hazard ratio [HR] ¼ 1.37, 95% confidence interval [CI] ¼ 1.19-1.55, P < 0.001). Age, male gender, diabetes mellitus, CKD, cirrhosis, history of uncomplicated PUD, PUB, and the use of tNSAIDs, ASA, or thienopyridines were also independent risk factors for developing UGIB (Table 2) . Subgroup analysis for different doses of coxibs via multivariate Cox regression analysis showed that high-dose coxibs had a higher HR than low-dose Coxibs for UGIB (Table 3) .
Among the coxibs users, univariate and multivariate Cox regression analysis showed that age, male gender, diabetes mellitus, CKD disease, cirrhosis, history of uncomplicated PUD, PUB, and H. pylori infection were independent risk factors for developing UGIB (Table 4) . The concomitant use of tNSAIDs, ASA, and thienopyridines also increased the risk of UGIB among coxibs users.
Discussion
In this nationwide cohort study, we demonstrated that patients taking coxibs have a higher risk of developing UGIB than propensity-matched controls (HR ¼ 1.37, 95% CI ¼ 1.19-1.55). Age, male gender, diabetes mellitus, CKD, cirrhosis, history of uncomplicated PUD, PUB, H. pylori infection, and the concomitant use of tNSAIDs, ASA, or thienopyridines were independent risk factors for UGIB among coxibs users. Of these risk factors, H. pylori infection (HR ¼ 3.61, 95% CI ¼ 3.08-4.14) and a history of PUB (HR ¼ 3.15, 95% CI ¼ 2.33-3.97) were associated with the highest risks for the occurrence of UGIB.
Most studies revealed that coxibs have effective antiinflammatory and pain control properties with less clinical UGI events than tNSAIDs [3] [4] [5] . One meta-analysis study assessed eight randomized controlled trials with 4,081 patients and showed that low-dose coxibs did not increase the risk of PUD compared with a placebo and that high-dose coxibs did not significantly increase the risk of PUD [6] . The discrepancy between the metaanalysis and our study may be due to the different patient populations. The meta-analysis excluded patients at high risk of UGIB, such as those with serious renal or hepatic disorders, a history of PUB, and the use of anticoagulants or antiplatelet drugs. Furthermore, some of the patients in our study were older than age 60 years, had a history of PUD/PUB; had CKD, Figure 1 Kaplan-Meier estimates of cumulative hazard of upper gastrointestinal bleeding of the patients categorized by cyclooxygenase-2 inhibitors users and the matched controls (P < 0.001 between the two groups by the log-rank test).
cirrhosis, osteoarthritis, rheumatoid arthritis, or other autoimmune diseases requiring long-term NSAIDs treatment; or concomitantly used steroids or anticoagulants [7] . Our study group also had some underlying comorbidities, such as COPD and diabetes mellitus, that also increased the risk of UGIB [10, [16] [17] [18] .
Previous studies showed that higher risk of developing PUB in tNSAIDs users was associated with male gender, age older than 60 years, a past history of PUD or its complications, taking larger doses of NSAIDs, and concomitant use of ASA or anticoagulants [9, 19, 20] .
Post hoc subgroup analysis showed that patients with prior UGI events did not have a significant reduction in the incidence of new ulcer complications despite the use of the coxibs [21] . There are few studies that identify the possible risk factors for UGIB in coxibs users with adjustment for underlying comorbidities. The results showed that diabetes mellitus, CKD, cirrhosis, history of uncomplicated PUD, and PUB are all risk factors for UGI bleeding in coxibs users.
Previous studies showed that concurrent use of SSRIs increased the risk of UGIB in tNSAIDs users [22, 23] . However, SSRIs did not increase the risk of UGIB among coxibs users in our study. The possible mechanisms by which SSRIs increase the occurrence of UGIB include the inhibition of serotonin reuptake by platelets, which leads to the depletion of serotonin and impairs platelet aggregation [11] . Coxibs that inhibit COX-2 function do not inhibit COX-1-dependent platelet aggregation, in contrast to tNSAIDs [24] . This is a possible reason why concurrent use of SSRIs did not increase the risk of UGIB in coxibs users. Further studies are needed to evaluate whether or not coxibs combined with SSRIs increase the risk of UGIB.
Other studies revealed that concomitant use of ASA increased the risk of UGIB in tNSAIDs users and coxibs users [25, 26] . However, our study showed that antiplatelet agents including ASA and thienopyridines were risk factors for UGIB in coxibs users. H. pylori infection increased the risk and had an additive effect for PUB in NSAID users [27, 28] . Our data also showed that H. pylori infection was an important risk factor for UGIB in coxibs users.
This study has several strengths. First, the Taiwanese NHIRD is one of the largest databases in the world and has comprehensive health care data that include enrollment files, claims data, and registry for drug prescriptions, and its use allows for a population-based design [10] [11] [12] . Second, few long-term, large-scale cohort studies have compared the occurrence of UGIB between coxibs users and propensity-matched controls while adjusting for underlying comorbidities and concurrent medications to reflect real-world conditions.
However, there are also several limitations to this study. First, data on smoking and alcohol use, which are potential confounders for UGIB, were not available in the NHIRD. Therefore, their influence on our findings is unknown. Second, there may be some bias as our study was a retrospective cohort study with an end point based on ICD-9 coding and data from the NHIRD. Third, prescriptions for PPIs in Taiwan are covered by the NHI program only after endoscopic confirmation of PUD/PUB or erosive esophagitis for four months, and data regarding the prophylactic use of PPIs were not available [12, 13] . Because PPIs can prevent UGIB or PUB-associated NSAIDs or coxibs [29] , over-thecounter use of PPIs would have resulted in underestimation of the HR of UGIB in coxibs users in our study. Fourth, the information about prescriptions from the NHIRD does not necessarily directly reflect medication use or ingestion. However, this problem may affect all population-based studies. In addition, data on the use of over-the-counter NSAIDs or PPIs were also not available.
In conclusion, coxibs users had a significantly higher occurrence of UGIB than matched controls in this nationwide population-based cohort study. Age, male gender, diabetes, CKD, cirrhosis, history of PUD, PUB, H. pylori infection, and the concomitant use of NSAIDs, ASA, or thienopyridines were all independent risk factors of UGIB among the coxibs users. Further studies are needed to assess whether the use of PPIs might play a protective role in these at-risk patients. 
